Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255398 | 0.84 | BUB1 (0.32) | BUB1USP2SMN1; SMN2NR1H2 | |
| SCHEMBL25301908 | 0.80 | BUB1 (0.38) | BUB1DDB1CRBNGRIN2BGRIN2C | |
| SCHEMBL31456782 | 0.80 | BUB1 (0.38) | BUB1DDB1CRBNGRIN2BGRIN2C | |
| SCHEMBL350967 | 0.80 | BUB1 (0.38) | BUB1DDB1CRBNGRIN2BGRIN2C | |
| SCHEMBL5743293 | 0.79 | BUB1 (0.32) | BUB1 | |
| SCHEMBL21244820 | 0.78 | BUB1 (0.40) | BUB1DDB1CRBNGRIN2BGRIN2C | |
| SCHEMBL992886 | 0.74 | USP2 (0.39) | GRIN2BGRIN2CUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL26915659 | 0.74 | GRIN2B (0.38) | BUB1DDB1CRBNGRIN2BGRIN2C | |
| SCHEMBL6364579 | 0.73 | PDE4A (0.38) | — | |
| SCHEMBL6364575 | 0.72 | GPR119 (0.39) | DDB1CRBNNR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2086995-A1 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064066-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1917269-A2 | INHIBITORS OF SERINE PROTEASES | Vertex Pharmaceuticals Incorporated (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1879910-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007025307-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006122188-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |